Core Viewpoint - A class action securities lawsuit has been filed against Fluor Corporation, alleging securities fraud that negatively impacted shareholders between February 18, 2025, and July 31, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that Fluor Corporation made false statements and concealed significant issues related to costs associated with infrastructure projects, including subcontractor design errors, price increases, and scheduling delays [3]. - It is alleged that these issues, along with reduced capital spending from customers and economic uncertainty, had a substantial negative impact on the company's business and financial results [3]. - The complaint further asserts that Fluor's financial guidance for FY 2025 was unreliable, overstating the effectiveness of its risk mitigation strategy and understating the impact of economic uncertainty [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a strong track record in securing recoveries for shareholders and has been ranked among the top securities litigation firms in the United States [5].

New York, New York--(Newsfile Corp. - November 12, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177026&wire=5&utm_campaign=14or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.Can ...

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc, alleging securities fraud that affected shareholders between May 16, 2024, and August 5, 2025 [2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for shareholders who were adversely affected by alleged securities fraud during the specified period [2]. - Defendants are accused of making false statements and concealing information regarding the improper inflation of cash flow, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions [3]. - The positive statements made by the defendants about the company's business and prospects are claimed to be materially false and misleading [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses in Marex Group plc stock during the relevant timeframe are encouraged to learn about their rights to seek recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP is highlighted as a nationally-recognized securities litigation firm with a strong track record in securing recoveries for aggrieved shareholders [5]. - The firm has been ranked in the Top 50 Report by ISS Securities Class Action Services for seven consecutive years, indicating its expertise in complex securities litigation [5].

Core Points - A class action securities lawsuit has been filed against aTyr Pharma, Inc. to recover losses for shareholders affected by alleged securities fraud between November 7, 2024, and September 12, 2025 [2][3] - The lawsuit claims that aTyr provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper off steroid usage [3][4] - The stock price of aTyr fell dramatically by 83.2%, from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint [5][4] Case Details - The complaint alleges that the defendants made overwhelmingly positive statements while concealing material adverse facts about the drug's efficacy [3] - The disappointing results of the EFZO-FIT study were disclosed during an investor call on September 15, 2025, where it was revealed that the study did not meet its primary endpoint [4] Next Steps - Shareholders who suffered losses during the relevant time frame are encouraged to seek information about their rights to recovery [6] - There is no cost or obligation for shareholders to participate in the recovery process [6] Legal Representation - Levi & Korsinsky LLP is highlighted as a nationally-recognized securities litigation firm with a strong track record in securing recoveries for shareholders [7] - The firm has been consistently ranked among the top securities litigation firms in the United States [7]

Core Points - A class action securities lawsuit has been filed against James Hardie Industries plc, targeting alleged securities fraud that affected shareholders between May 20, 2025, and August 18, 2025 [2][3] - The lawsuit claims that the company made false statements and concealed negative facts regarding its North America segment, including deteriorating consumer demand and excessive inventory issues [3] Company Details - The complaint alleges that the primary driver of growth in the North America segment was overstocking rather than genuine consumer demand, leading to excessive inventory at distributors [3] - The lawsuit seeks to recover losses for shareholders who were adversely affected during the specified time frame, regardless of whether they still hold their shares [4] Legal Representation - Levi & Korsinsky LLP, a nationally recognized securities litigation firm, is representing the shareholders in this case, boasting a strong track record in securing recoveries for aggrieved investors [5]

Core Viewpoint - A class action securities lawsuit has been filed against Fortinet, Inc. to recover losses incurred by shareholders due to alleged securities fraud between November 8, 2024, and August 6, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Fortinet's management made false statements and concealed information regarding the refresh cycle of their products, which was not as profitable as represented [3]. - It is alleged that the company misrepresented the number of FortiGate firewalls eligible for upgrades and misled investors about the momentum of the refresh cycle, which was pushed through more rapidly than communicated [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP is highlighted as a reputable securities litigation firm with a strong track record in securing recoveries for shareholders, having been recognized in the Top 50 Report for seven consecutive years [5].

Core Viewpoint - A class action securities lawsuit has been filed against KBR, Inc. to recover losses for shareholders affected by alleged securities fraud between May 6, 2025, and June 19, 2025 [2][3]. Group 1: Lawsuit Details - The complaint alleges that KBR, Inc. made false statements regarding its partnership with the U.S. Department of Defense's Transportation Command, claiming there were no issues with HomeSafe's ability to fulfill a global household goods contract, despite known concerns [3]. - The lawsuit asserts that the statements made by KBR regarding its business operations and prospects were materially false and misleading, lacking a reasonable basis during the relevant time [3]. Group 2: Next Steps for Shareholders - Shareholders who suffered losses in KBR, Inc. stock during the specified timeframe are encouraged to learn about their rights to seek recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a nationally recognized securities litigation firm, has a strong track record of securing hundreds of millions of dollars for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [5].

Core Viewpoint - The article discusses a class action lawsuit against Six Flags Entertainment Corporation, alleging that the company and its executives misled investors regarding the financial health and operational needs of the company prior to its merger with Cedar Fair, L.P. [1][3] Company Overview - Six Flags Entertainment Corporation operates amusement parks and was formerly known as CopperSteel HoldCo, Inc. [2] Merger Details - The merger between Legacy Six Flags and Cedar Fair was completed on July 1, 2024, with Six Flags stock initially trading above $55 per share [4]. - Following the merger, the stock price plummeted to as low as $20 per share, representing a nearly 64% decline [4]. Allegations of Misrepresentation - The lawsuit claims that the registration statement for the merger failed to disclose significant underinvestment in Legacy Six Flags, which required millions in additional capital to maintain operations [3]. - It is alleged that the new CEO, Selim Bassoul, implemented cost-cutting measures that degraded operational competence and guest experience, further exacerbating the company's financial issues [3]. Legal Proceedings - Investors who purchased Six Flags stock in connection with the merger have until January 5, 2026, to seek appointment as lead plaintiff in the class action lawsuit [1].

Core Viewpoint - Telix Pharmaceuticals Limited is facing a securities class action lawsuit following significant stock declines due to a regulatory subpoena and an FDA rejection letter [1] Group 1: Legal Proceedings - The lawsuit, titled Thomas v. Telix Pharmaceuticals Ltd., seeks to represent investors who acquired Telix securities between February 21, 2025, and August 28, 2025 [3] - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [2][8] Group 2: Company Statements and Allegations - The litigation focuses on Telix's statements regarding its prostate cancer therapeutic candidates TLX591 and TLX592, as well as its kidney cancer detection candidate Zircaix [4] - During the class period, Telix claimed progress in its therapeutic pipeline and emphasized its global manufacturing capabilities as a competitive advantage [5] - The lawsuit alleges that Telix made false and misleading statements, overstating the progress of its prostate cancer candidates and the quality of its supply chain [5] Group 3: Regulatory Issues - On July 22, 2025, Telix disclosed an SEC investigation into its disclosures related to the development of its prostate cancer therapeutic candidates, leading to a sharp decline in stock price [6] - On August 28, 2025, Telix received a Complete Response Letter from the FDA for its Zircaix BLA, citing deficiencies in manufacturing and requesting additional data [7]

Accessibility StatementSkip Navigation PHILADELPHIA, Nov. 12, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than Januar ...